Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dense Breasts Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

NCT03063619
View directory record Official record
Conditions
Mammographically Dense Breast
Interventions
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
5
States / cities
Tampa, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Jun 26, 2026, 5:00 AM EDT
Not yet recruiting Phase 2 Interventional

Mammogram Pretreatment With Ulipristal Acetate

NCT07434128
View directory record Official record
Conditions
Mammography Screening, Breast Density
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Mammogram, Survey Administration, Ulipristal Acetate
Procedure · Other · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

Dose Dense TC + Pegfilgrastim Support for Breast Cancer

NCT01671319
View directory record Official record
Conditions
Female Breast Cancer
Interventions
docetaxel + cyclophosphamide + pegfilgrastim
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jun 26, 2026, 5:00 AM EDT
Completed No phase listed Observational

A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.

NCT00816530
View directory record Official record
Conditions
Breast Cancer
Interventions
Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
Device
Lead sponsor
U-Systems, Inc.
Industry
Eligibility
25 Years and older · Female only
Enrollment
15,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Indio, California • Monterey, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Early Phase 1 Interventional

Detection and/or Evaluation of Dense Breast Abnormalities Using Tomosynthesis and Digital Mammography

NCT00722059
View directory record Official record
Conditions
Breast Neoplasms, Breast Abnormalities
Interventions
Breast Tomosynthesis
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
30 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Jun 26, 2026, 5:00 AM EDT
Completed No phase listed Observational

Delphinus SoftVue™ ROC Reader Study

NCT03972605
View directory record Official record
Conditions
Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening, Abnormal Breast Screening
Interventions
Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

NCT00861705
View directory record Official record
Conditions
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Bevacizumab, Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
448
States / cities
Jonesboro, Arkansas • Rogers, Arkansas • Berkeley, California + 309 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jun 26, 2026, 5:00 AM EDT
Not yet recruiting Not applicable Interventional

Molecular Breast Imaging (MBI)-Guided Biopsy

NCT07114679
View directory record Official record
Conditions
Breast Cancer Detection, Breast Neoplasm, Molecular Imaging, Biopsy, Dense Breasts
Interventions
Molecular Breast Imaging, MBI-guided biopsy
Device
Lead sponsor
Smart Breast Corp.
Industry
Eligibility
21 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jun 26, 2026, 5:00 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts

NCT04854304
View directory record Official record
Conditions
Breast Diseases
Interventions
Fast Breast Abbreviated Magnetic Renounce Imaging
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

NCT00591851
View directory record Official record
Conditions
Breast Cancer
Interventions
AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Jun 26, 2026, 5:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Automated Breast Ultrasound

NCT02386176
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2020 · Synced Jun 26, 2026, 5:00 AM EDT
Terminated Phase 2 Interventional

Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer

NCT00080626
View directory record Official record
Conditions
Breast Cancer
Interventions
pegfilgrastim, docetaxel, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Jun 26, 2026, 5:00 AM EDT
Active, not recruiting No phase listed Observational

Non-contrast DWI for Supplemental Screening

NCT03607552
View directory record Official record
Conditions
Breast Cancer
Interventions
Non-contrast DWI, Non-contrast MRI
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
269 participants
Timeline
2018 – 2029
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 2 Interventional

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

NCT00146562
View directory record Official record
Conditions
Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
Interventions
Darbepoetin Alfa, Pegfilgrastim, Paclitaxel, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Harold J. Burstein, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
6
States / cities
Boston, Massachusetts • Lowell, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Jun 26, 2026, 5:00 AM EDT
Recruiting No phase listed Observational

Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue

NCT06127797
View directory record Official record
Conditions
Breast Cancer
Interventions
Questionnaire/Interview
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Full-Field Digital Mammography With Digital Breast Tomography for Screening Call-Back Rates

NCT01236781
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Screening Tomosynthesis, Diagnostic Tomosynthesis
Device
Lead sponsor
American College of Radiology
Other
Eligibility
25 Years and older · Female only
Enrollment
558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

NCT00193206
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Epirubicin, Albumin-bound Paclitaxel
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Fort Myers, Florida • Jacksonville, Florida • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

NCT00723125
View directory record Official record
Conditions
Breast Cancer
Interventions
Abraxane, Carboplatin, Avastin
Drug
Lead sponsor
William Sikov MD
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
5
States / cities
Bridgeport, Connecticut • New Haven, Connecticut • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Jun 26, 2026, 5:00 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts

NCT02042456
View directory record Official record
Conditions
Breast Cancer
Interventions
Digital Breast Tomosynthesis, Automated Whole Breast Ultrasound, Full Field Digital Mammography
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Jun 26, 2026, 5:00 AM EDT
Terminated Phase 2 Interventional Results available

Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer

NCT01194869
View directory record Official record
Conditions
Breast Cancer
Interventions
Sorafenib, Cisplatin, Paclitaxel
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Jun 26, 2026, 5:00 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

NCT01498588
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast
Interventions
Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2016 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Dual-energy (DE) Contrast-enhanced (CE) Digital Mammography

NCT02995980
View directory record Official record
Conditions
Breast Cancer
Interventions
Dual-Energy Contrast-Enhanced (DECE) mammography, digital mammography
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jun 26, 2026, 5:00 AM EDT
Not listed No phase listed Observational

A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue

NCT05268224
View directory record Official record
Conditions
Breast Cancer Screening
Interventions
Schirmer Strip
Diagnostic Test
Lead sponsor
Namida Lab
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Jun 26, 2026, 5:00 AM EDT
Terminated Phase 3 Interventional Results available

Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue

NCT03199963
View directory record Official record
Conditions
Mammographic Breast Density
Interventions
4-OH tamoxifen, Placebo
Drug
Lead sponsor
BHR Pharma, LLC
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Mesa, Arizona • Tucson, Arizona • Beverly Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jun 26, 2026, 5:00 AM EDT